TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Breathing Retraining on Pulmonary Function, Exercise Capacity, Quality of Life and Cardiac Autonomic Function in Patients With COPD
Brief Summary: Conventional pulmonary rehabilitation programs improve exercise tolerance, peripheral muscle strength, and health related quality of live but not pulmonary function in patients with chronic obstructive pulmonary disease (COPD). The role of breathing retraining techniques in the rehabilitation of patients with COPD remains unclear. The hypothesis to be tested in this study is that pulmonary function, cardio-pulmonary exercise capacity, health related quality of life and cardiac autonomic modulation of patients with COPD who undergo pulmonary rehabilitation plus breathing retraining will be better than that of patients undergoing a conventional pulmonary rehabilitation.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diaphragmatic breathing training; Type: EXPERIMENTAL; Interventions: Other: Diaphragmatic breathing training | Intervention Type: OTHER; Name: Diaphragmatic breathing training; Assigned to Arm(s): Diaphragmatic breathing training
B: Arm Label: FT; Type: EXPERIMENTAL; Interventions: Behavioral: Breathlessness Intervention Service (BIS) | Arm Label: WL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Best supportive care (Standard care) | Intervention Type: BEHAVIORAL; Name: Breathlessness Intervention Service (BIS); Assigned to Arm(s): FT | Intervention Type: BEHAVIORAL; Name: Best supportive care (Standard care); Assigned to Arm(s): WL
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ventilation feedback, Behavioral: exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ventilation feedback | Intervention Type: BEHAVIORAL; Name: ventilation feedback; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): 1, 2
D: Arm Label: pulmonary rehabilitation, no breathing retraining; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: breathing retraining; Type: NO_INTERVENTION; Interventions: Other: respiratory biofeedback | Intervention Type: OTHER; Name: respiratory biofeedback; Assigned to Arm(s): breathing retraining

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: School-Based Asthma Therapy: Stage 2 Effectiveness Study
Brief Summary: Asthma is the most common chronic illness of childhood, and hospitalization rates are increasing. In the US, impoverished children and children from minority ethnic and racial backgrounds suffer disproportionately from asthma. While National Heart, Lung, and Blood Institute (NHLBI) guidelines recommend daily preventive medications for all children with mild persistent to severe persistent asthma, studies indicate that many children in the US who should receive preventive medications are not receiving them. The overall goal of this project is to target an ethnically diverse population of inner-city schoolchildren with asthma and explore a school-based program to reduce asthma morbidity. We hypothesize that children receiving a comprehensive school-based intervention will experience less asthma-related morbidity compared to children receiving usual care. Our comprehensive school-based intervention consists of both administration of recommended preventive asthma medications in school (with dose adjustments according to NHLBI guidelines) and an environmental tobacco smoke (ETS) reduction program in the home for smoke-exposed children. Our secondary hypothesis is that, among the subgroup of smoke-exposed children, those who receive the school-based intervention with ETS reduction will experience less asthma morbidity than those who receive usual care.


Options:
A: Arm Label: Case Group; Type: N/A; Interventions: N/A | Arm Label: Control Group; Type: N/A; Interventions: Other: MyMediHealth access | Intervention Type: OTHER; Name: MyMediHealth access; Assigned to Arm(s): Control Group
B: Arm Label: Educational Program; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Program | Arm Label: Asthma information for teachers; Type: NO_INTERVENTION; Interventions: Other: Usual Asthma Information for teachers | Intervention Type: BEHAVIORAL; Name: Educational Program; Assigned to Arm(s): Educational Program | Intervention Type: OTHER; Name: Usual Asthma Information for teachers; Assigned to Arm(s): Asthma information for teachers
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: School-based Care; Type: EXPERIMENTAL; Interventions: Behavioral: School-based Care | Intervention Type: BEHAVIORAL; Name: School-based Care; Assigned to Arm(s): School-based Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Web-based Asthma Management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based asthma education | Intervention Type: BEHAVIORAL; Name: Tailored Web-based Asthma Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Generic web-based asthma education; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Behavioral and Drug Treatment of Overactive Bladder in Men
Brief Summary: The primary aim of this project is to evaluate the effectiveness of combined behavioral + drug therapy compared to behavioral treatment alone and drug therapy alone as a way to improve outcomes in the treatment of OAB symptoms in men. We hypothesize that combined therapy will result in better outcomes than either behavioral or drug therapy alone. The second aim is to compare two methods of implementing combined therapy: simultaneously as initial therapy vs. stepped therapy, in which therapies are combined following initial behavioral or drug therapy alone. The third aim is to examine the costs and cost-effectiveness of combined behavioral + drug therapy compared to behavioral or drug therapy alone.


Options:
A: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1
B: Arm Label: Rééducation; Type: EXPERIMENTAL; Interventions: Other: Pelvic floor muscle training with physiotherapist, Other: Written information about kegel exercises | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Written information about kegel exercises | Intervention Type: OTHER; Name: Pelvic floor muscle training with physiotherapist; Assigned to Arm(s): Rééducation | Intervention Type: OTHER; Name: Written information about kegel exercises; Assigned to Arm(s): Control, Rééducation
C: Arm Label: Behavioral Treatment alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy (Tolterodine + tamsulosin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine + tamsulosin | Arm Label: Combined Behavioral + Drug Therapy; Type: EXPERIMENTAL; Interventions: Other: Combined Behavioral + Drug Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Treatment alone | Intervention Type: DRUG; Name: Tolterodine + tamsulosin; Assigned to Arm(s): Drug Therapy (Tolterodine + tamsulosin) | Intervention Type: OTHER; Name: Combined Behavioral + Drug Therapy; Assigned to Arm(s): Combined Behavioral + Drug Therapy
D: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise classes with pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise classes with pelvic floor muscle training; Assigned to Arm(s): Exercise group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Comparison Between Two Surgical Techniques With Acellular Dermal Matrix Graft in the Treatment of Gingival Recessions
Brief Summary: The aim of this study is to test a surgical technique for the treatment of gingival recessions. The hypothesis of the study is to promote greater root coverage and better healing.


Options:
A: Arm Label: Connective tissue graft (CTG); Type: SHAM_COMPARATOR; Interventions: Procedure: Connective tissue graft | Arm Label: Connective tissue graft plus laser (CTG+L); Type: EXPERIMENTAL; Interventions: Procedure: Connective tissue graft | Intervention Type: PROCEDURE; Name: Connective tissue graft; Assigned to Arm(s): Connective tissue graft (CTG), Connective tissue graft plus laser (CTG+L)
B: Arm Label: test and control; Type: EXPERIMENTAL; Interventions: Procedure: Periodontal surgery to gingival recessions | Intervention Type: PROCEDURE; Name: Periodontal surgery to gingival recessions; Assigned to Arm(s): test and control
C: Arm Label: CAF+MC+EMD; Type: EXPERIMENTAL; Interventions: Device: Mucograft, Device: Emdogain, Procedure: Coronally Advanced flap | Arm Label: CAF+MC; Type: ACTIVE_COMPARATOR; Interventions: Device: Mucograft, Procedure: Coronally Advanced flap | Arm Label: CAF+EMD; Type: ACTIVE_COMPARATOR; Interventions: Device: Emdogain, Procedure: Coronally Advanced flap | Arm Label: CAF; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Coronally Advanced flap | Intervention Type: DEVICE; Name: Mucograft; Assigned to Arm(s): CAF+MC, CAF+MC+EMD | Intervention Type: DEVICE; Name: Emdogain; Assigned to Arm(s): CAF+EMD, CAF+MC+EMD | Intervention Type: PROCEDURE; Name: Coronally Advanced flap; Assigned to Arm(s): CAF, CAF+EMD, CAF+MC, CAF+MC+EMD
D: Arm Label: Mucograft + CAF; Type: EXPERIMENTAL; Interventions: Device: Mucograft | Arm Label: CAF; Type: EXPERIMENTAL; Interventions: Procedure: Coronally advanced flap (CAF) | Intervention Type: DEVICE; Name: Mucograft; Assigned to Arm(s): Mucograft + CAF | Intervention Type: PROCEDURE; Name: Coronally advanced flap (CAF); Assigned to Arm(s): CAF

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of IN.PACT Admiral(TM) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease
Brief Summary: The objective of this Study is to evaluate the safety and efficacy of the IN.PACT Admiral® drug coated PTA balloon, utilized for the dilatation of the narrowed sections of the artery, as compared to other standard (non drug coated) PTA balloons. The IN.PACT Admiral, besides the mechanical dilatation effect typical of all PTA balloons, releases a drug (paclitaxel) from the balloon surface into the vessel walls. This drug absorption is intended to limit the chances and the entity of artery re-narrowing over time.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Device: paclitaxel coated balloon catheter (device with drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: paclitaxel coated balloon catheter (device with drug) | Intervention Type: DEVICE; Name: paclitaxel coated balloon catheter (device with drug); Assigned to Arm(s): 1, 2
B: Arm Label: Drug-Coated Balloon (DCB); Type: EXPERIMENTAL; Interventions: Device: Drug-Coated Balloon (DCB) | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA Balloon: Balloon Angioplasty | Intervention Type: DEVICE; Name: Drug-Coated Balloon (DCB); Assigned to Arm(s): Drug-Coated Balloon (DCB) | Intervention Type: DEVICE; Name: PTA Balloon: Balloon Angioplasty; Assigned to Arm(s): Standard PTA
C: Arm Label: standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: nitinol stent implantation | Arm Label: DEB; Type: EXPERIMENTAL; Interventions: Device: paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation | Intervention Type: DEVICE; Name: paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation; Assigned to Arm(s): DEB | Intervention Type: DEVICE; Name: nitinol stent implantation; Assigned to Arm(s): standard PTA
D: Arm Label: Lutonix Catheter; Type: EXPERIMENTAL; Interventions: Device: Lutonix Catheter | Arm Label: Standard uncoated Balloon Angioplasty Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard uncoated Balloon Angioplasty Catheter | Intervention Type: DEVICE; Name: Lutonix Catheter; Assigned to Arm(s): Lutonix Catheter | Intervention Type: DEVICE; Name: Standard uncoated Balloon Angioplasty Catheter; Assigned to Arm(s): Standard uncoated Balloon Angioplasty Catheter

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Nursing Intervention to Enhance Comfort and Promote Psychological Well-Being in Children During and Following PICU Hospitalization: A Pilot Study
Brief Summary: Children who become critically ill and require Pediatric Intensive Care Unit (PICU)hospitalization may develop negative psychological outcomes following discharge. This pilot study will test a nursing intervention that seeks to promote child comfort, sleep and psychological well-being during and following PICU hospitalization.

Study objectives are to:

1. test the feasibility and acceptability of a PICU comfort care intervention that can be administered by nursing staff
2. examine the feasibility and acceptability of data collection procedures
3. pilot test outcome measures
4. determine effect sizes to inform sample size calculation for a future multi-centred randomized controlled trial (RCT).

The intervention will take place in the PICU, and consists of a parental soothing activity followed by a quiet period in which earmuffs are placed over the child's ears to block noise. Children's sleep time and comfort level will be monitored in the PICU, and the investigators will follow them for 3 months post-discharge to examine the effects of the intervention on psychological well-being.


Options:
A: Arm Label: Comfort Care; Type: EXPERIMENTAL; Interventions: Other: Comfort Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Comfort Care; Assigned to Arm(s): Comfort Care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
B: Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Other: Music Therapy | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Music Therapy; Assigned to Arm(s): Interventional
C: Arm Label: Dynamic light; Type: EXPERIMENTAL; Interventions: Other: Dynamic Light | Arm Label: Normal Light; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Dynamic Light; Assigned to Arm(s): Dynamic light
D: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: acupuncture | Arm Label: Sham Acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: sham acupuncture | Intervention Type: DEVICE; Name: acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: sham acupuncture; Assigned to Arm(s): Sham Acupuncture

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease
Brief Summary: This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease. Droxidopa is being studied to determine the effects on blood pressure changes upon standing up (orthostatic challenge). Symptoms and activity measurements, including patient reported falls, will be evaluated to determine the effectiveness of the study drug.

Symptoms of NOH may include any of the following:

* Dizziness, light-headedness, feeling faint or feeling like you may blackout
* Problems with vision (blurring, seeing spots, tunnel vision, etc.)
* Weakness
* Fatigue
* Trouble concentrating
* Head \& neck discomfort (the coat hanger syndrome)
* Difficulty standing for a short time or a long time
* Trouble walking for a short time or a long time

The study duration is a maximum of approximately 14 weeks including up to 2 weeks for screening, up to 2 weeks for proper dose finding, followed by an 8 week treatment period and a follow-up visit after 2 weeks. A sufficient number of patients will be screened to allow approximately 211 randomized patients. An extension study is also available to continue treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation only.


Options:
A: Arm Label: Dual Task Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dual Task Group | Arm Label: Single Task Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Single Task Group | Intervention Type: BEHAVIORAL; Name: Dual Task Group; Assigned to Arm(s): Dual Task Group | Intervention Type: BEHAVIORAL; Name: Single Task Group; Assigned to Arm(s): Single Task Group
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3, Dietary Supplement: calcium | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium, Other: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Arm 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Azilect®; Type: EXPERIMENTAL; Interventions: Drug: Azilect® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Azilect®; Assigned to Arm(s): Azilect®
D: Arm Label: Droxidopa; Type: EXPERIMENTAL; Interventions: Drug: Droxidopa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Droxidopa; Assigned to Arm(s): Droxidopa | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage
Brief Summary: The specific aims of this study are to:

1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset.
2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the subjects' quality of life as measured by EuroQol at 3 months.
3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of hematoma expansion (defined as increase from baseline hematoma volume of at least 33%) and in the change from baseline peri-hematoma volume at 24 hours on the serial computed tomographic (CT) scans.
4. Assess the safety of the intensive treatment relative to the standard treatment in the proportion of subjects with treatment-related serious adverse events (SAEs) within 72 hours.


Options:
A: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Induced hypertension; Type: ACTIVE_COMPARATOR; Interventions: Other: Induced hypertension | Intervention Type: OTHER; Name: Induced hypertension; Assigned to Arm(s): Induced hypertension
B: Arm Label: Standard SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Arm Label: Intensive SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Intervention Type: DRUG; Name: Intravenous nicardipine hydrochloride; Assigned to Arm(s): Intensive SBP Reduction Arm, Standard SBP Reduction Arm
C: Arm Label: Clazosentan 5 mg/h; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan 5 m/h | Arm Label: Clazosentan 15 mg/h; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan 15 mg/h | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Clazosentan 5 m/h; Assigned to Arm(s): Clazosentan 5 mg/h | Intervention Type: DRUG; Name: Clazosentan 15 mg/h; Assigned to Arm(s): Clazosentan 15 mg/h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Candesartan Cilexetil; Type: EXPERIMENTAL; Interventions: Drug: Candesartan Cilexetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Candesartan Cilexetil; Assigned to Arm(s): Candesartan Cilexetil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Telephone Contact and Professional Coordination for Preventing Recurrent Suicidal Acts
Brief Summary: The prevention of recurrent suicidal about people who have made a suicide attempt is a major strand in the prevention of suicide. It is estimated that 10-15 % of people who made a suicide attempt die by suicide. Recidivism rate of suicide increases even faster than the subject is close to the index suicide attempt. A one month recurrence rate is 5 %, 12-25 % at one year. Most people who made a suicide attempt receive ambulatory monitoring. On this population, there is a low adherence to care.

The main objective of the study is to test the effectiveness of a prevention program of recurrent suicidal acts for people who made a suicide attempt.

The secondary objectives of this study are the assessment of adherence to care; the identification of sub - populations benefiting most from this program; the evaluation of the possible generalization level of the program (eligibles persons rate) and its feasibility level.


Options:
A: Arm Label: Interventional group; Type: EXPERIMENTAL; Interventions: Other: Usual treatment and Prevention program | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Treatment | Intervention Type: OTHER; Name: Usual treatment and Prevention program; Assigned to Arm(s): Interventional group | Intervention Type: OTHER; Name: Usual Treatment; Assigned to Arm(s): Control group
B: Arm Label: Positive Psychology; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Psychology | Arm Label: Organizational Skills; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Positive Psychology; Assigned to Arm(s): Positive Psychology | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Organizational Skills
C: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Interpersonal effectiveness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interpersonal effectiveness | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness | Intervention Type: BEHAVIORAL; Name: interpersonal effectiveness; Assigned to Arm(s): Interpersonal effectiveness
D: Arm Label: meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Central Meditation and Imagery Therapy | Arm Label: wait list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Central Meditation and Imagery Therapy; Assigned to Arm(s): meditation

Answer: A